October 12, 2021
Hong Kong to donate 7.5 million doses of COVID-19 Vaccine AstraZeneca through COVAX
The Government of the Hong Kong Special Administrative Region (HKSAR) will donate 7.5 million doses of COVID-19 Vaccine AstraZeneca through the COVAX (Covid-19 Vaccines Global Access) Facility over the next six months, marking a significant contribution to the global response to the COVID-19 pandemic, supporting broad and equitable vaccine access worldwide.
COVAX is a global initiative co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi (the Vaccines Alliance) and the World Health Organization, which works with governments and manufacturers to accelerate the development, production and equitable access to COVID-19 vaccines around the world, including low-to-middle income countries, many of which are in Asia.
Carol Mui, General Manager, AstraZeneca Hong Kong said: “As the first global pharmaceutical company to join COVAX in 2020, we are pleased to support this initiative and enable broad and equitable access to our vaccine. We will continue to work collaboratively with COVAX and the government of HKSAR to fight the pandemic in the months ahead.”
Of 585 million individuals who have received at least one dose of COVID-19 Vaccine AstraZeneca as of September 2021, the vaccine has prevented over 105,000 deaths and over 620,000 hospitalisations worldwide.1
To date, more than 1.5 billion doses of AstraZeneca’s vaccine have been released for supply to over 170 countries globally, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries. AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020 and continues to supply its COVID-19 vaccine globally at no profit via COVAX, complemented by direct deliveries to governments.
Notes
COVID-19 Vaccine AstraZeneca
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For more information, please contact emma.chu@astrazeneca.com.
References
COVAX is a global initiative co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi (the Vaccines Alliance) and the World Health Organization, which works with governments and manufacturers to accelerate the development, production and equitable access to COVID-19 vaccines around the world, including low-to-middle income countries, many of which are in Asia.
Carol Mui, General Manager, AstraZeneca Hong Kong said: “As the first global pharmaceutical company to join COVAX in 2020, we are pleased to support this initiative and enable broad and equitable access to our vaccine. We will continue to work collaboratively with COVAX and the government of HKSAR to fight the pandemic in the months ahead.”
Of 585 million individuals who have received at least one dose of COVID-19 Vaccine AstraZeneca as of September 2021, the vaccine has prevented over 105,000 deaths and over 620,000 hospitalisations worldwide.1
To date, more than 1.5 billion doses of AstraZeneca’s vaccine have been released for supply to over 170 countries globally, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries. AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020 and continues to supply its COVID-19 vaccine globally at no profit via COVAX, complemented by direct deliveries to governments.
Notes
COVID-19 Vaccine AstraZeneca
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For more information, please contact emma.chu@astrazeneca.com.
References
- AZD1222 lives and hospitalisations prevented data on file. Data on File Number: REF-126333 September 21, 2021. AstraZeneca UK Ltd.